The use of aspirin and P2Y12 inhibitors on admission was more frequent in CAD- and NSTEMI patients compared to patients without coronary artery disease and prescription of ACE inhibitors and β-blockers was more common among CAD- than among no-CAD patients. This evidence concerns the gene P2RY12 and coronary artery disorder.